Revenue increased 58.1%
Revenue changed +58.1% from the comparable as-filed period.
$73.4M→$116.1M3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →PL financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating margin moved 1283 bp higher
Operating margin changed +1283 basis points from the comparable as-filed period.
-24.47%→-11.64%3 prior comparisons
Net income increased 58.6%
Net income changed +58.6% from the comparable as-filed period.
-$22.6M→-$9.4M2 prior comparisons
Cash & equivalents increased 129.2%
Cash & equivalents changed +129.2% from the comparable as-filed period.
$181.1M→$415.1M2 prior comparisons
Research & development increased 45.5%
Research & development changed +45.5% from the comparable as-filed period.
$24.2M→$35.2M3 prior comparisons
Gross profit increased 55.3%
Gross profit changed +55.3% from the comparable as-filed period.
$42.3M→$65.6M3 prior comparisons
Operating income increased 24.8%
Operating income changed +24.8% from the comparable as-filed period.
-$18.0M→-$13.5M3 prior comparisons
SBC / revenue moved 364 bp lower
SBC / revenue changed -364 basis points from the comparable as-filed period.
18.34%→14.70%3 prior comparisons
Operating income decreased 53.2%
Operating income changed -53.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
-$22.8M→-$34.9M3 prior comparisons
Operating margin moved 269 bp lower
Operating margin changed -269 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
-34.36%→-37.06%3 prior comparisons
Capital expenditure increased 113.2%
Capital expenditure changed +113.2% from the comparable as-filed period. The change ranks at the 83th percentile of 6 prior comparable changes.
$8.1M→$17.3M6 prior comparisons
Revenue increased 42.1%
Revenue changed +42.1% from the comparable as-filed period.
$66.3M→$94.2M3 prior comparisons
Cash & equivalents increased 175.8%
Cash & equivalents changed +175.8% from the comparable as-filed period.
$133.5M→$368.1M2 prior comparisons
Research & development increased 44.8%
Research & development changed +44.8% from the comparable as-filed period.
$23.1M→$33.4M3 prior comparisons
Free-cash-flow proxy changed across a sign change
Free-cash-flow proxy changed -120.3% from the comparable as-filed period. The change ranks at the 50th percentile of 6 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 5 consecutive comparable moves in the opposite direction.
$9.2M→-$1.9M6 prior comparisons
Capex / revenue moved 613 bp higher
Capex / revenue changed +613 basis points from the comparable as-filed period.
12.25%→18.39%2 prior comparisons
Gross profit increased 37.7%
Gross profit changed +37.7% from the comparable as-filed period.
$36.6M→$50.4M3 prior comparisons
Operating cash flow decreased 11.0%
Operating cash flow changed -11.0% from the comparable as-filed period. The change ranks at the 0th percentile of 6 prior comparable changes. This reverses 5 consecutive comparable moves in the opposite direction.
$17.3M→$15.4M6 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.